Who we are and what we do
GSK.ca
Our news
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
ZEJULA is approved in Canada for first-line maintenance treatment of women with advanced ovarian cancer
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Transparency reporting
At GSK, we’re committed to building transparency as we believe it enhances trust for patients and our healthcare system. Since 2017, GSK has voluntarily disclosed in aggregate payments to Healthcare Professionals (HCPs) and payments to Healthcare Organizations (HCOs). Starting this year, we are expanding the reporting to include payments to individual HCPs. You can view our transparency reporting here.
Learn more about transparency reporting
Explore our products
We make a wide range of prescription medicines, prescribed vaccines and consumer healthcare products.
Working at GSK
Looking for a new career? Find out about working at GSK and how to apply for a job.
